|
|
|
مراجع علم الأدوية النفسية
1.
أحمد عكاشه
(1980): الطب النفسي المعاصر، الطبعة
الرابعة، القاهرة، مكتبة الأنجلو المصرية. 2.
أحمد
عكاشه، أوول رافسون، ليو هولستر (1981):
العقاقير النفسية، القاهرة، مكتبة الأنجلو
المصرية. 3.
إيمان عبد
الله البنا (1991): دينامية العلاقة بين
الاغتراب وتعاطي المواد المخدرة لدى طلبة
الجامعة. رسالة ماجستير غير منشورة، كلية
الآداب، جامعة عين شمس. 4.
حسين فايد
(1994): دراسة مقارنة في الشخصية والأعراض
السيكوسوماتية بين متعاطي العقاقير المثبطة
والعقاقير المنشطة. رسالة دكتوراه غير
منشورة، كلية الآداب، جامعة عين شمس. 5.
سامي عبد
القوي (1986): خصائص الشخصية المرتبطة
بالتدخين: دراسة في الفروق بين الجنسين لدى
طلبة الجامعة. رسالة ماجستير غير منشورة،
كلية الآداب، جامعة عين شمس. 6.
سامي عبد
القوي (1995): علم النفس الفسيولوجي، الطبعة
الثانية، القاهرة، مكتبة النهضة المصرية. 7.
سامي عبد
القوي (2001): علم النفس العصبي: الأسس وطرق
التقييم. الإمارات، مطبوعات جامعة
الإمارات. 8.
سيلفانو
آريتي (1991): الفصامي كيف نفهمه ونساعده.
الكويت، سلسلة عالم المعرفة، العدد 156. 9.
عادل
الدمرداش (1982): الإدمان: مظاهره وعلاجه.
الكويت، سلسلة عالم المعرفة العدد 56. 10.
عبد الحليم
منتصر (1995): الجامع لمفردات الأدوية والأغذية
لإبن البيطار. سلسلة تراث الإنسانية،
القاهرة، الهيئة العامة للكتاب. 11.
عبد
اللطيف عثمان (1985):
الصرع والتشنجات بين
الحقيقة والخرافة. الطبعة الأولى، القاهرة،
دار الكتاب الجامعى. 12.
عبد
المجيد الشاعر، ربى الطالب، رشدي قطاش (2004): علم
الدواء. الأردن، دار اليازوري للنشر
والتوزيع. 13.
علي
عبد الله الدفاع (1986): إسهام علماء العرب
والمسلمين في الصيدلة. بيروت، مؤسسة
الرسالة. 14.
محمد
أحمد النابلسي (1994): معجم العلاج النفسي
الدوائي. بيروت، دار ومكتبة الهلال. 15.
موجنس
دام (1984): الصرع: تشخيصه وعلاجه. ترجمة عبد
الغفور عبد المغيث، بسيوني محمد، الرياض، دار
المريخ. 16.
Abbot
R, Liozon A (1986): Neuroleptic Malignant Syndrome. Brit. J. Psychiatry,
148:47. 17.
Abdel-Tawab
S (1974): Text book of Applied Pharmacology, 18.
American
Psychiatric Association (1994): Diagnostic and Statistical Manual of Mental
Disorders. 19.
Andermann
F. (1994): Oxcarbamazepine: Experience and Future Role. Epilepsia,
35(supp.3): S25-S28. 20.
Barbee
G, Jamhour N. (2002): Lamotrigine as an augmentation agent in
treatment-resistant depression. Journal of Clinical Psychiatry, 63,
737-741. 21.
Barkic
J, Filakovic P, Radanovic L, Koic O, et al. (2003): The influence of respirdone
on cognitive functions in schizophrenia. Coll Antropol, 27, Suppl 1(1): 111-8. 22.
Bear
L, Rauch S, Ballantine, H. (1995): Cingulotomy for intractable Obsessive
compulsive disorder. Archive General Psychiatry, 52: 384-392. 23.
Black
K, Shea C, Dursun S, et al. (2000): Selective serotonin reuptake inhibitor
discontinuation syndrome: proposed diagnostic criteria. J Psychiatry
Neuroscience;25(3):255-61 24.
Beaty
W, Hames K, Blanco C. et al. (1996): Visuospatial perception, construction and
memory of alcoholism. J Studies Alcohol, 57: 136-143. 25.
Benedetti
K (1998): Low dose clozapine in
acute and continuation treatment of severe Borderline Personality Disorder.
J Clinical Psychiatry; 59,103-7. 26.
Brebion
G, Amador X, Smith M, Malaspina D, Sharif Z (2000): Depression, psychomotor
retardation, negative symptoms, and memory in schizophrenia. Neuropsychiatry
Neuropscholo Behav Neurol, 13: 177-183. 27.
Breier
B, Kirkpatrick C, et al. (1994): Effects of clozapine on positive and negative
symptoms in outpatients with schizophrenia. Am J Psychiatry; 151; 20- 6. 28.
Brodie
M(1995): Cognitive functions and antiepileptic. 21st
International Epilepsy Congress, 29.
Bowden
C, Karren N. (2002): Lamotrigine in the treatment of bipolar disorder. Expert
Opinion in Pharmacotherapy, 3, 1513-1519. 30.
Brown
E, Nejtek V, Perantie D, Orsulak P, Bobadilla L (2003): Lamotrigine in patients
with bipolar disorder and cocaine dependence, Journal of Clinical Psychiatry
, 64, 197-201. 31.
Bullen
J(1990): Cognitive function
and epilepsy. In: D., Ross R,
Chadweck R, Crawford (Eds.) Epilepsy in young
people, Chichester, New York, Joho Wiley & Sons. 32.
Byrd
A (1999): Serotonine and its use. Available on-line http://serndip.brynmawr.edu/bb/neuro99/web/Byrd.html 33.
Calabrese
J, Shelton M, Rapport D, Kimmel S. ( 2002): Bipolar disorders and the
effectiveness of novel anticonvulsants Clin Psychiatry;63 Suppl 3:5-9. 34.
Caley
C (1997): Extrapyramidal reactions and the selective serotonin-reuptake
inhibitors. The Annals of Pharmacotherapy, 31, 1481-1489. 35.
Ciannini
A (1991): Marijuana and Psychopathology. In: Dual Diagnosis of Substance
Abuse, M. Gold, A Slaby (eds.), Marcel Dekker inc., 36.
Cummings,
J.(1999): Understanding Parkinson’s disease. JAMA, Vol.281 (4)
:376-384. 37.
Curran
H, Java R, Lader, M (1995): Cognitive and psychomotor effects of
oxacarbamazepine. Epilepsia, 32,1,26. 38.
Cuesta
M, Peralta V, Zarzuela A (2001): Effects of olanzapine and other antipsychotic
on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr
Res, Marsh 1; 48 (1): 17- 28. 39.
Dam
M(1994): Practical aspects of oxcarbazepine treatment. Epilepsia,
35, (supp.3): S23-S25. 40.
Denenberg
V, Kim D, Palmiter D (2004): The role of dopamine in learning, memory, and
performance of a water escape task. Behavior Brain Research.;148(1-2):73-8 41.
Dodrill
C, Troupin A (1991): Neuropsychological
effects of Carbamazepine and phenytoin: A reanalysis. Neurology,
41, 141-143. 42.
Dominguez
R ,Goodnick P (1995): Adverse events after the abrupt discontinuation of
paroxetine. Pharmacotherapy, 15, (6), 778-780. 43.
Drummer
O (2002): Benzodiazepines: Effects on Human Performance and behavior; Forensic
Science Review, 14:1. 44.
Duncan
J, Shorvon S, Trimble M (1990): Effects of removal of phenytoin, Carbamazepine,
and valproat on cognitive function. Epilepsia, 31,
584-591. 45.
Ellen E (2000): A
Novel Antidepressant. Hippocrates, vol. 14, no. 4. Available on line http://www.hipocrates.com/archive/april2000/04departments/04horizon.html 46.
Ernst C, Goldberg
J(2003):Antidepressant properties of anticonvulsant drugs for bipolar disorder. J
Clin Psychopharmacol;23(2):182-92. 47.
Frawell J, Lee Y,
Hirtz D, et al. (1990): Phenobarbital
for febrile seizures- effects on intelligence and on seizure recurrence. 48.
Garcia-Campayo J,
Sanz-Carrillo C. (2001): Gabapentin for the treatment of patients with
Somatization disorder Clin Psychiatry;62(6):474. 49.
Gallassi R,
Morreal A, Lorusso S, et al.(1990): Cognitive
effects of valproat. Epilepsy Research, 5, 160-164. 50.
Gaspers
P (2003): The developmental role of serotonin. Nature Reviews Neuroscience,
4: 1002-1012. 51.
Gerlach
J, Berckert O (1996): Advancement in CNS Drugs. Recent advances and
considerations in the treatment of schizophrenia. J. Clinical Psychiatry,
57: 318-320. 52.
Gram
L(1994): Clinical experience with oxcarbazepine. Epilepsia,
35(supp.3): S21-S22. 53.
Green
M, Marshall B, Wirshing W et al (1997): Does Respirdone improve verbal working
memory in treatment-resistant schizophrenia? Am J Psychiat, 153: 321-330. 54.
Green
M, Marder S, Glynn S, et al. (2002): The Neurocognitive effects of low –dose
haloperidol: a two- year comparison with respirdone. Biol Psychiat, 51:
972-978. 55.
Gross
C (2002): Serotonine 1A receptor acts during development to establish normal
anxiety- like behavior in adult. Nature, 28: 377-380. 56.
Haddad
P (1997): Newer antidepressants and the discontinuation syndrome. Journal of
Clinical Psychiatry, 57, (7), 17-21. 57.
Hadorn
D. (2002): Cannabis studies: Cognition, Learning, and Motivation: Studies
Showing A Negative Effects on Cognition. JAMA, Marsh 6: 287 (9): 1172-4. 58.
Harvey
P, Keefe R (2001): studies of cognitive changes in patients with schizophrenia
following novel antipsychotic treatment. Am J Psychiat, 158: 176-184. 59.
Harvey
P, Green M, McGurk S, Meltzer H (2003): Changes in cognitive functioning with
respirdone and olanzapine treatment: a large-scale, double-blind, randomized
study. Psychopharmacology, 169: 404-411. 60.
Harvey
P, Siu C, Romano S (2004): Randomized, controlled, double- blind, multicenter
comparison of cognitive effects of ziprasidone versus olanzapine in acutely ill
inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology,
172: 324-332. 61.
Jaff
J, Epstien S (1991): Opiod. In: Ciraulo, D., Shader, R. (eds.) clinical
Manual of Chemical Dependence. American Psychiatric Press Inc., Washington. 62.
Kapur
S, Seeman P (2001): Does fast dissociation from the dopamine D2 receptor explain
the action of atypical antipsychotics? : A new hypothesis. Am J Psychiat,
158: 360-369. 63.
Kara
E. (2003): SSRI discontinuation syndrome Awareness as an approach to prevention,
Postgraduate Medicine, vol.114, no.2,79-84, available online: http://www.postgradmed.com/issues/2003/08_03/ditto.htm 64.
Karper
S, Resinger E (2003): Cognitive effects and antipsychotics. Psychopharmacology,
28: 27-38. 65.
Keranen,
T( 1990): Discontinuation of antiepileptic drugs. In: M. Sillanpaa ,J Svein, G
Blennow, M Dam, (Eds.). Pediatric
epilepsy, Wrightson Biomedical pupl., Peters field, 66.
Kulisvesky
J, Paseual-Sedano B(1999): Parkinson’s disease and cognition,
Neurologica, 14 (suppl.1): 72-81. 67.
Lane
R, Hanlon J (1999): Cognitive and psychomotor effects of antidepressants wih
emphasis on selective serotonin reuptake inhibitors and the depressed elderly
patient. German J Psychiatry, 2: 1-42. Available on-line: www.gjpsy.uni-goettingen.de/gjp-article-lane.htm 68.
Lejoyeux
M, Ades J. (1997): Antidepressant discontinuation: a review of the literature. J
Clin Psychiatry;58(Suppl 7):11-6 69.
Leonard
B (1992): Pharmacological differences of serotonin reuptake inhibitors and
possible clinical relevance. Drugs, 43, Supplement 2, 3-10. 70.
Lehmann
H, Ban T (1997): The history of the polypharmacology of schizophrenia. Canadian
J. Psychiatry, 42: 152-162. 71.
Levy
G, Tong M, Cote L, et al. (2000):Motor impairment in Parkinson disease. Neurology,
55(4): 539-544. 72.
Liddle
P (2000): Cognitive impairment in schizophrenia: its impact on social
functioning. Acta Psychiatrica Scand Suppl, 400: 11-16. 73.
Loring
D, Meador K (2004): Cognitive side effects of antiepileptic drugs in children. Neurology,
62: 872-877. 74.
McKeith I (2000):
Spectrum of Parkinson disease, Parkinson dementia, and Lewy Body
dementia. Neurol Clin, 18(4): 865-902. 75.
Meltzer
H (2003): Atypical antipsychotic drugs improve cognition in schizophrenia.
Biol Psychiat, 53: 265-267. 76.
Moselhy
H, George G, Khan A (2001): Frontal lobe changes in alcoholism: A review of he
literature. Alcohol and Alcoholism, vol. 36, No. 5: 357-368. 77.
National
Parkinson Foundation (NPF)(2001): Mental slowing, intellectual decline,
cognitive impairment and memory loss in Parkinson disease. [on-line]
Available: http://www.parkinson.org/mental.htm.
78.
National
Institute for Clinical Excellence (May, 2005): Guidance on the use of newer
atypical antipsychotic drugs for treatment of schizophrenia. Technology
Appraisal Guidance no. 43. Available on line: http://www.nice.org.uk 79.
National
Institute for Clinical Excellence (November, 2005): Guidance on the use of
electroconvulsive therapy, Technology Appraisal 59. Available on line: http://www.nice.org.uk 80.
Price
L (1990): Serotonin reuptake inhibitors in depression and anxiety, an overview. Annals
of Clinical Psychiatry, 2, 165-172. 81.
Podewils
L, Lykestos C (2002): Tricyclic Antidepressants and Cognitive decline. Psychosomatics,
43: 31-35.
82.
Purdon
S, Malla A, Labelle A (2001): Neuropsychological changes in patients with
schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry
Neuroscience, 26: 137-149. 83.
Rakic
G, Lidow M, Gallager D (1990): Overlap of dopaminergic, adrenergic, and
Serotonergic receptors and complementarity of their subtypes in primate
prefrontal cortex. J. Neuroscience, vol. 10, 2125-2138. 84.
Robillard
M , Conn D (2002): Lamotrigine use in geriatric patients with bipolar
depression, Canadian Journal of Psychiatry, 2002, 47, 767-770. 85.
Rosenbaum
J, Zajecka J (1997): Clinical management of antidepressant discontinuation. J
Clin Psychiatry;58(Suppl 7):37-40 86.
Rubin
H (2000,December,8): Parkinson’s disease.[on-line]
Available: http://www.therubins.com/illness/parkinson.htm 87.
Sabers
A(1990): Cognitive function and epilepsy. In:M Sillanpaa, J
Svein, G Blennow, M Dam, (Eds.).
Pediatric epilepsy ,Wrightson Biomedical pupl., 88.
Saltz
B, Woerner M, Robinson D (2000): Side effects of antipsychotic drugs: Avoiding
and minimizing their impact in elderly. Postgraduate Medicine, Vol.107,
No. 2. 89.
Santarlasci
B, Messori A (2003): clinical trial response and dropouts with olanzapine versus
respirdone. Ann Pharmacol, 37: 556-563. 90.
Schatzberg
A, Haddad P, Kaplan E, et al. (1997): Serotonin reuptake inhibitor
discontinuation syndrome: a hypothetical definition. Discontinuation Consensus
Panel. J Clin Psychiatry;58(Suppl 7):5-10 91.
Seeman
P (2002): Atypical antipsychotics: mechanism of action. Can J Psychiatry,
47: 27-38. 92.
Sharma
T (2002): Atypical antipsychotics and cognition in schizophrenia. Arch Gen
Psychiatry, 59: 571-572. 93.
Sharma
T, Antonova L (2003): Cognitive function in schizophrenia. Deficits, functional
consequences, and future treatment. Psychiat Clin North Am, 26: 25-40. 94.
Solowij
N (1998): Cannabis and cognitive functioning. 95.
Solowij
N, Stephens R, Roffman R, Babor T, et al (2002): Cognitive functioning of
long-term heavy cannabis users seeking treatment. Available on-line: http://davidhadron.com/cannabis/cognegative.htm 96.
Tarazi
F (2001): Neuropharmacology of dopamine receptors: Implications in
neuropsychiatric diseases. Sultan Qaboos Journal for Scientific Research,
vol.3, no.2, 87-104. 97.
Tzambazis
K, Stough C (2000): Alcohol impairs speed of information processing and simple
and choice reaction time and differentially impairs higher-order cognitive
abilities. Alcohol and Alcoholism, 35: 428-435. 98.
Versiani M
(1999): Reboxetine, a unique selective NRI, prevent relapse and recurrence in
long term treatment of major depressive disorder. J Clinical Psychiatry,
60: 400-406. 99.
Viallette
F (2000): Diagnostic criteria for idiopathic Parkinson disease.
Rev Neurol, 156, suppl3:30-35. 100.
Volavka J, Czobor
P, Sheitman B, et al. (2002): clozapine, olanzapine, and haloperidol in the
treatment of patients with chronic schizophrenia and schizoaffective disorder. Am
J Psychiatry, 159: 255- 262. 101.
Wagner M, Quednow
B, Westheid J, Schlaepefer T, et al. (2004): Cognitive improvement in
schizophrenic patients does not require a Serotonergic mechanism: Randomized
controlled trial of olanzapine versus amisulpride. Neuropsychopharmacology,
…. 102.
What is
Serotonine? Available on-line
www.hku.hk/psychi/emotion/whatis_serotonin.html 103.
Weiss E, Bilder
R, Fleischhacker W (2002): The effects of second generation antipsychotics on
cognitive functioning and psychosocial outcomes in schizophrenia. Psychopharmacology,
162: 11- 17. 104. Yatham L., Kusumakar, V., Calabrese, J. (2002): Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations, Journal of Clinical Psychiatry, 63, 275-283.
|